Finding new uses for existing drugs to treat Alzheimer's Disease
Compound repositioning for Alzheimer's Disease using knowledge graphs, insurance claims data, and gene expression complementarity
This study is looking at how some already-approved medications might be used in new ways to help treat Alzheimer's Disease, using smart technology and lots of data to find promising options that could make a difference for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10766135 on NIH RePORTER |
What this research studies
This research investigates how existing FDA-approved drugs can be repurposed to treat Alzheimer's Disease. It utilizes a large library of compounds and employs advanced techniques such as machine learning and analysis of extensive insurance claims data to identify potential drug candidates. Additionally, the study examines gene expression patterns to find compounds that may reverse changes associated with Alzheimer's. By integrating these diverse data sources, the research aims to uncover effective treatments for this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for Alzheimer's Disease using existing medications.
How similar studies have performed: Previous research has shown promise in drug repositioning for various conditions, suggesting potential success for this novel approach in Alzheimer's treatment.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Su, Andrew I — Scripps Research Institute, the
- Study coordinator: Su, Andrew I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.